By a News Reporter-Staff News Editor at Clinical Trials Week -- -Neurotrope, Inc. (OTCQB:NTRP) (the "Company") announced that Dr. Larry D. Altstiel, M.D., Ph.D. has been appointed to the Company's Scientific Advisory Board. Dr. Altstiel is an expert in several neurodegenerative disease states with respect to their potential causes and treatments. He has extensive clinical and operational experience in pharmaceutical development and has published many related articles and abstracts in his field of study (see also Neurotrope, Inc.).
Dr. Altstiel is currently the Chief Executive Officer of Provectra, an early-stage biotechnology company developing novel gene therapy for neurodegenerative diseases. Dr. Altstiel is responsible for all of Provectra's product development activities, while leading Provectra toward commercializing products based upon its proprietary gene therapy technologies.
>From 2007 to 2013, Dr. Altstiel was Vice President Neuroscience Clinical Development, Neuroscience Therapeutic Area Clinical Lead, at Pfizer Inc. His principal responsibilities were directing the PGRD Neuroscience Research Unit clinical research, which included governance, operational and budgetary responsibilities for: preclinical biology and first in human studies; supervising of transitional medical plans and related external alliances; supervising clinical teams conducting early phase clinical research from translational medicine through proof of concept and subsequent Phase 3 clinical trials.
Dr. Altstiel's other positions included Senior Vice President, Head of Global Clinical Development, at Schwarz Biosciences, Inc., Vice President for Research Operations at Eisai Medical Research Inc. and Schering-Plough and Senior Clinical Research Physician and Group Leader for Neurodegenerative Diseases Clinical and Discovery Research for Alzheimer's Disease, Parkinson's Disease and Stroke at Eli Lilly and Company. Dr. Altstiel also has gained extensive experience in psychiatry and neurology at Mount Sinai School of Medicine, Columbia Presbyterian Medical Center and Hospital and The Bronx Veteran's Administration Medical Center.
Dr. Altstiel has published over 60 publications and abstracts over the last 35 years on topics including neurodegenerative diseases such as Alzheimer's Disease and their related pharmacogenetics and potential treatments. He earned his B.S. in Chemistry / Physics at the University of Illinois, his Ph.D. in Cell Biology, Virology and Physical Chemistry at The Rockefeller University and his M.D. at The University of Miami, Miller School of Medicine.
"I am very pleased to join Neurotrope'sAdvisory Board and help with their product development," stated Dr. Altstiel. "The Company's novel approach to diagnosing and treating neurodegenerative disease is very exciting, and I look forward to contributing to Neurotrope's efforts in developing diagnostics and treatments for Alzheimer's Disease and other neurodegenerative diseases."
The Company's Chief Executive Officer, Dr. Jim New, said, "We are very pleased to have formalized a collaborative relationship with Dr. Altstiel. Dr. Altstiel's expertise in developing neurodegenerative disease products through research and development and shepherding those products through clinical trials will be of great help to Neurotrope as it continues to develop its neurodegenerative disease products."
Keywords for this news article include: Hospital, Chemicals, Chemistry, Neuroscience, Therapeutics, Neurotrope Inc., Clinical Research, Pre-Trial Research, Nervous System Diseases, Neurodegenerative Diseases, Clinical Trials and Studies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC